Picture of Tilray Brands logo

TLRY — Tilray Brands News Story

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapValue Trap

Tilray Q2 revenue rises, helped by international medical cannabis sales growth

Overview

The cannabis maker's Q2 revenue rose 3% to $217.5 mln

Adjusted net loss for Q2 improved slightly compared to last year

Company holds $292 mln in cash and marketable securities

Outlook

Tilray expects U.S. federal cannabis rescheduling to unlock new market opportunities

Company plans to leverage existing infrastructure for U.S. medical cannabis expansion

Tilray reaffirms fiscal 2026 Adjusted EBITDA guidance at $62 mln – $72 mln

Result Drivers

INTERNATIONAL CANNABIS GROWTH - International medical cannabis revenue increased by 36%, contributing to overall cannabis revenue growth

DISTRIBUTION SEGMENT - Distribution net revenue reached a record high of $85.3 million, up from $67.6 million

BEVERAGE REVENUE DECLINE - Beverage net revenue decreased to $50.1 million from $63.1 million, impacting overall revenue growth

Key Details

MetricBeat/MissActualConsensus Estimate
Q2 Revenue$217.51 mln
Q2 Adjusted EPS-$0.02
Q2 EPS-$0.41
Q2 Net Income-$43.51 mln
Analyst Coverage The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell" Wall Street's median 12-month price target for Tilray Brands Inc is C$13.60, about 9.2% above its January 7 closing price of C$12.45 Press Release: ID:nGNXCLswC For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Tilray Brands

See all news